<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2153838-B1" country="EP" doc-number="2153838" kind="B1" date="20140108" family-id="40129682" file-reference-id="318259" date-produced="20180826" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146588935" ucid="EP-2153838-B1"><document-id><country>EP</country><doc-number>2153838</doc-number><kind>B1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-08777143-A" is-representative="YES"><document-id mxw-id="PAPP154851127" load-source="docdb" format="epo"><country>EP</country><doc-number>08777143</doc-number><kind>A</kind><date>20080611</date><lang>JA</lang></document-id><document-id mxw-id="PAPP174946785" load-source="docdb" format="original"><country>EP</country><doc-number>08777143.2</doc-number><date>20080611</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140548139" ucid="JP-2007155780-A" load-source="docdb"><document-id format="epo"><country>JP</country><doc-number>2007155780</doc-number><kind>A</kind><date>20070612</date></document-id></priority-claim><priority-claim mxw-id="PPC140558000" ucid="JP-2008035038-A" load-source="docdb"><document-id format="epo"><country>JP</country><doc-number>2008035038</doc-number><kind>A</kind><date>20080215</date></document-id></priority-claim><priority-claim mxw-id="PPC140549372" ucid="JP-2008060705-W" load-source="docdb"><document-id format="epo"><country>JP</country><doc-number>2008060705</doc-number><kind>W</kind><date>20080611</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130813</date></intention-to-grant-date><search-report-dispatch-date><date>20120829</date></search-report-dispatch-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989327092" load-source="docdb">A61P   1/12        20060101ALI20130704BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327093" load-source="docdb">A61P  31/14        20060101ALI20130704BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327094" load-source="docdb">A01N  31/02        20060101AFI20130704BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327095" load-source="docdb">A61K   9/06        20060101ALI20130704BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327096" load-source="docdb">A61P  31/04        20060101ALI20130704BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327097" load-source="docdb">A01N  25/30        20060101ALI20130704BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327098" load-source="docdb">A61K   9/00        20060101ALI20130704BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327099" load-source="docdb">A61P  43/00        20060101ALI20130704BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327100" load-source="docdb">A01P   3/00        20060101ALI20130704BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327101" load-source="docdb">A01P   1/00        20060101ALI20130704BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327102" load-source="docdb">A61K  31/05        20060101ALI20130704BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327103" load-source="docdb">A61Q  17/00        20060101ALI20130704BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327104" load-source="docdb">A61K  47/10        20060101ALI20130704BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327105" load-source="docdb">A01N  37/02        20060101ALI20130704BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327106" load-source="docdb">A01N  37/36        20060101ALI20130704BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327107" load-source="docdb">A01N  65/00        20090101ALI20130704BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327108" load-source="docdb">A61K   8/97        20060101ALI20130704BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327109" load-source="docdb">A61K  31/194       20060101ALI20130704BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327110" load-source="docdb">A61K  31/216       20060101ALI20130704BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327111" load-source="docdb">A61K  36/896       20060101ALI20130704BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989327112" load-source="docdb">A61K  47/12        20060101ALI20130704BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-2051754616" load-source="docdb" scheme="CPC">A61K  36/896       20130101 LI20150521BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2051754631" load-source="docdb" scheme="CPC">A61K   9/06        20130101 LI20150521BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2051756259" load-source="docdb" scheme="CPC">A61K  36/18        20130101 FI20150521BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2051756709" load-source="docdb" scheme="CPC">A61K   8/97        20130101 LI20150521BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2051756995" load-source="docdb" scheme="CPC">A61K  47/12        20130101 LI20150521BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2051757813" load-source="docdb" scheme="CPC">A61K   9/0014      20130101 LI20150521BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2051758979" load-source="docdb" scheme="CPC">A01N  65/08        20130101 LI20150519BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2051759279" load-source="docdb" scheme="CPC">A61K  47/10        20130101 LI20150521BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2051759607" load-source="docdb" scheme="CPC">A61K  31/19        20130101 LI20150521BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2051760807" load-source="docdb" scheme="CPC">A61K  31/05        20130101 LI20150521BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2051761374" load-source="docdb" scheme="CPC">A61K  31/194       20130101 LI20150521BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2051762327" load-source="docdb" scheme="CPC">A61K  36/44        20130101 LI20150521BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2051762969" load-source="docdb" scheme="CPC">A61K   9/0019      20130101 LI20150521BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2051763369" load-source="docdb" scheme="CPC">A61Q  17/005       20130101 LI20150521BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2051764382" load-source="docdb" scheme="CPC">A01N  65/00        20130101 LI20150521BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2051764460" load-source="docdb" scheme="CPC">A61K  31/216       20130101 LI20150521BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2051765146" load-source="docdb" scheme="CPC">A61K   9/0053      20130101 LI20150521BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132371438" lang="DE" load-source="patent-office">ANTI-NOROVIRUS-WIRKSTOFF UND ZUSAMMENSETZUNG DAMIT</invention-title><invention-title mxw-id="PT132371439" lang="EN" load-source="patent-office">ANTI-NOROVIRUS AGENT, AND COMPOSITION COMPRISING THE SAME</invention-title><invention-title mxw-id="PT132371440" lang="FR" load-source="patent-office">AGENT ANTI-NOROVIRUS ET COMPOSITION LE COMPRENANT</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR919536351" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>UNIV HIROSHIMA</last-name><address><country>JP</country></address></addressbook></applicant><applicant mxw-id="PPAR919508633" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>HIROSHIMA UNIVERSITY</last-name></addressbook></applicant><applicant mxw-id="PPAR919529646" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>ALTAN CO LTD</last-name><address><country>JP</country></address></addressbook></applicant><applicant mxw-id="PPAR919541454" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>ALTAN CO., LTD.</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919513007" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>SHIMAMOTO TADASHI</last-name><address><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919515555" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>SHIMAMOTO, TADASHI</last-name></addressbook></inventor><inventor mxw-id="PPAR919025513" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>SHIMAMOTO, TADASHI</last-name><address><street>c/o GRADUATE SCHOOL OF BIOSPHERE SCIENCE HIROSHIMA UNIVERSITY 4-4 Kagamiyama 1-chome</street><city>Higashi-Hiroshima-shi Hiroshima 739-8528</city><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919512787" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>TSUJI TORU</last-name><address><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919519852" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>TSUJI, TORU</last-name></addressbook></inventor><inventor mxw-id="PPAR919025515" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>TSUJI, TORU</last-name><address><street>c/o ALTAN CO. LTD. 11-10 Higashikojiya 3-chome Ota-ku</street><city>Tokyo 144-0033</city><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919522409" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>NAKAI YOSHIAKI</last-name><address><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919531201" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>NAKAI, YOSHIAKI</last-name></addressbook></inventor><inventor mxw-id="PPAR919025514" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>NAKAI, YOSHIAKI</last-name><address><street>c/o ALTAN CO. LTD. 11-10 Higashikojiya 3-chome Ota-ku</street><city>Tokyo 144-0033</city><country>JP</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR919025516" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Hiroshima University</last-name><iid>100997338</iid><address><street>3-2, Kagamiyama 1-chome Higashi-Hiroshima-shi</street><city>Hiroshima 739-8511</city><country>JP</country></address></addressbook></assignee><assignee mxw-id="PPAR919025518" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>Altan Co., Ltd.</last-name><iid>101084046</iid><address><street>11-10 Higashikojiya 3-chome</street><city>Ota-ku Tokyo 144-0033</city><country>JP</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR919025517" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Matthews, Derek Peter</last-name><iid>100028988</iid><address><street>Dehns St Bride's House 10 Salisbury Square</street><city>London EC4Y 8JD</city><country>GB</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="JP-2008060705-W"><document-id><country>JP</country><doc-number>2008060705</doc-number><kind>W</kind><date>20080611</date><lang>JA</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2008153077-A1"><document-id><country>WO</country><doc-number>2008153077</doc-number><kind>A1</kind><date>20081218</date><lang>JA</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549791810" load-source="docdb">AT</country><country mxw-id="DS549789756" load-source="docdb">BE</country><country mxw-id="DS549874400" load-source="docdb">BG</country><country mxw-id="DS549889365" load-source="docdb">CH</country><country mxw-id="DS549789765" load-source="docdb">CY</country><country mxw-id="DS549791811" load-source="docdb">CZ</country><country mxw-id="DS549881901" load-source="docdb">DE</country><country mxw-id="DS549789766" load-source="docdb">DK</country><country mxw-id="DS549789767" load-source="docdb">EE</country><country mxw-id="DS549898238" load-source="docdb">ES</country><country mxw-id="DS549874401" load-source="docdb">FI</country><country mxw-id="DS549889366" load-source="docdb">FR</country><country mxw-id="DS549881906" load-source="docdb">GB</country><country mxw-id="DS549789768" load-source="docdb">GR</country><country mxw-id="DS549881907" load-source="docdb">HR</country><country mxw-id="DS549791812" load-source="docdb">HU</country><country mxw-id="DS549889367" load-source="docdb">IE</country><country mxw-id="DS549789773" load-source="docdb">IS</country><country mxw-id="DS549874406" load-source="docdb">IT</country><country mxw-id="DS549789774" load-source="docdb">LI</country><country mxw-id="DS549874407" load-source="docdb">LT</country><country mxw-id="DS549925873" load-source="docdb">LU</country><country mxw-id="DS549874408" load-source="docdb">LV</country><country mxw-id="DS549874409" load-source="docdb">MC</country><country mxw-id="DS549925874" load-source="docdb">MT</country><country mxw-id="DS549925875" load-source="docdb">NL</country><country mxw-id="DS549889368" load-source="docdb">NO</country><country mxw-id="DS549925876" load-source="docdb">PL</country><country mxw-id="DS549898239" load-source="docdb">PT</country><country mxw-id="DS549806490" load-source="docdb">RO</country><country mxw-id="DS549925877" load-source="docdb">SE</country><country mxw-id="DS549881908" load-source="docdb">SI</country><country mxw-id="DS549889373" load-source="docdb">SK</country><country mxw-id="DS549789775" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data></bibliographic-data><description mxw-id="PDES63961351" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001">Technical Field</heading><p id="p0001" num="0001">The present invention relates to an anti-norovirus agent that has high efficacy against the norovirus, that is safe for the human body, and that contains an extract from a plant of the genus <i>Diospyros</i> containing tannin, and an anti-norovirus composition that contains the anti-norovirus agent and is useful for disinfection and infection control against the norovirus.</p><heading id="h0002">Background Art</heading><p id="p0002" num="0002">The norovirus is a single-stranded (plus strand) RNA virus that belongs to Caliciviridae norovirus, that has a diameter of approximately 30 nm, and that has no envelope. The norovirus was first identified as a pathogen responsible for food poisoning and acute gastroenteritis in the U.S.A. in 1963 and since then has been detected worldwide. In food poisoning cases caused by the norovirus in the past six years in Japan, the annual incidence of food poisoning cases is approximately 270 (approximately 18% of the total number of<!-- EPO <DP n="2"> --> food poisoning cases), and the annual number of patients is approximately 10,000 (approximately 30% of the total number of victims of food poisoning). Sources of primary infection include food materials, for example, bivalves, such as oysters, and sources of secondary infection include vomit and excrement of patients. In particular, secondary infection is greatly responsible for the spread of infection. The norovirus is highly infectious; 10 or more viral particles are believed to be sufficient for infection.</p><p id="p0003" num="0003">A vaccine or a therapeutic agent for the norovirus has not yet been developed, and the only measure against norovirus infection is to heat high-risk foods and disinfect cooking utensils and hands. However, benzalkonium chloride and ethanol presently used as antimicrobial agents for various purposes in places for cooking and processing food, such as eating establishments, facilities providing meals, and factories, have no recognized efficacy against the norovirus. Chlorine bleach (such as sodium hypochlorite), iodine preparations (such as povidone-iodine), and aldehyde agents (such as glutaral) are believed to be efficacious to some extent. However, taking the safety of the human body into account, application of these agents to fingers of workers and cooking utensils is not appropriate, not to<!-- EPO <DP n="3"> --> mention the direct application of these agents to food.</p><p id="p0004" num="0004">Against this backdrop, there is a strong demand for an anti-norovirus detergent and disinfectant that can keep fingers of workers and cooking utensils hygienic in a safe way. However, few components that have a high antiseptic effect on the norovirus and are safe for the human body have been found, and such an ideal detergent has not been developed. By way of example, <patcit id="pcit0001" dnum="JP2007045732A"><text>JP 2007-045732 A</text></patcit> discloses a disinfectant solution that has norovirus-inactivating activity and that clearly is safe and mild on the skin. The disinfectant solution contains 0.05% to 0.5% by weight polyhexamethylene biguanide compound, preferably further contains 40% to 80% by weight alcohol, and has a pH in the range of 9 to 12.</p><p id="p0005" num="0005">"The astringent juice of the persimmon" produced by fermenting an extract from a persimmon has been used as Chinese herbal medicine, such as an antihypertensive, in China for a long time and is also familiar to Japanese as folk medicine. The astringent juice of the persimmon is rich in tannin and is believed to have astringency (the property of contracting a tissue by combining to a protein or another substance), antimicrobial action, and deodorizing action.<!-- EPO <DP n="4"> --> Utilizing this functionality, for example, <patcit id="pcit0002" dnum="JP2005232043A"><text>JP 2005-232043 A</text></patcit> discloses an antimicrobial dental composition that contains an extract from the astringent juice of the persimmon, the extract being covered with cyclodextrin to improve its handleability and antimicrobial properties, and <patcit id="pcit0003" dnum="JP2001172861A"><text>JP 2001-172861 A</text></patcit> discloses a textile product in which fibers impregnated with a solution containing a functional agent (such as a deodorant or an antimicrobial agent) and the astringent juice of the persimmon or persimmon tannin are bound utilizing the stypsis of persimmon tannin. Methods of preparing persimmon juice are also disclosed in <patcit id="pcit0004" dnum="JP2004065174A"><text>JP 2004-065174 A</text></patcit> and <patcit id="pcit0005" dnum="JP2002253183A"><text>JP 2002-253183 A</text></patcit>.</p><p id="p0006" num="0006"><patcit id="pcit0006" dnum="JP2006206558A"><text>JP 2006-206558 A</text></patcit> discloses an antimicrobial composition that contains a tannin substance, a fatty acid ester, and a chelating agent (Claim 1). Examples of the tannin substance include tannic acid, pyrocatechol, gallic acid, persimmon tannin, tea tannin, and gall tannin (Claim 4). However, the efficacy of the antimicrobial composition is demonstrated only for tannic acid in <i>Escherichia coli</i> and <i>Staphylococcus aureus</i> (Examples), and <patcit id="pcit0007" dnum="JP2006206558A"><text>JP 2006-206558 A</text></patcit> does not specifically disclose a technical idea that only persimmon tannin of the tannin substances has marked anti-norovirus characteristics and that persimmon tannin is a very important component of an<!-- EPO <DP n="5"> --> anti-norovirus composition.</p><p id="p0007" num="0007">The structure and a purification method of tannin contained in <i>Diospyros kaki</i> (condensed tannin) can be found in the following two papers (Matsuo and Itoo, 1981a/1981b: Non-patent Literatures 1 and 2).
<ul><li>[Non-patent Literature 1] <nplcit id="ncit0001" npl-type="s"><text>MATSUO, Tomoaki and ITOO, Saburo (1981a): Comparative Studies of Condensed Tannins from Several Young Fruits. J. Japan. Soc. Hort. Sci., 50(2), 262-269</text></nplcit>.</li><li>[Non-patent Literature 2] <nplcit id="ncit0002" npl-type="s"><text>MATSUO, Tomoaki and ITOO, Saburo (1981b): A Simple and Rapid Purification Method of Condensed Tannins from Several Young Fruits. Agric. Biol. Chem., 45(8), 1885-1887</text></nplcit>.</li></ul></p><heading id="h0003">Disclosure of Invention</heading><heading id="h0004">Technical Problem</heading><p id="p0008" num="0008">It is an object of the present invention to provide an anti-norovirus agent that has high norovirus-inactivating activity and is safe for the human body, and an anti-norovirus composition that contains the anti-norovirus agent and is useful for disinfection and infection control against the norovirus.<!-- EPO <DP n="6"> --></p><heading id="h0005">Solution to Problem</heading><p id="p0009" num="0009">To solve the problems described above, the present inventors searched substances and plant components approved as food or food additives, that is, materials safe to eat, for a substance having anti-norovirus activity, and completed the present invention by finding that an extract from a plant of the genus <i>Diospyros</i> containing tannin has marked anti-norovirus activity.</p><p id="p0010" num="0010">Thus, an anti-norovirus agent for use as a non-therapeutic disinfecting agent according to the present invention, and a pharmaceutical composition according to the present invention, are characterized by containing, as an active ingredient, an extract from a plant of the genus <i>Diospyros</i> containing tannin (hereinafter referred to as a "persimmon extract").</p><p id="p0011" num="0011">The persimmon extract is preferably produced by heating squeezed juice or an extract from the fruit of a plant of the genus <i>Diospyros</i> or treating the squeezed juice or the extract with an alcohol. The persimmon extract is preferably an extract containing at least condensed tannin, for example, an extract from <i>Diospyros kaki.</i><!-- EPO <DP n="7"> --></p><p id="p0012" num="0012">Such an anti-norovirus agent is preferably used as an active ingredient for the norovirus in a composition in combination with an alcohol, a surfactant, an antimicrobial agent, a humectant, a cosmetic fat and oil, and other substances.</p><p id="p0013" num="0013">Thus, an anti-norovirus composition according to the present invention is characterized by containing the anti-norovirus agent and at least one selected from the group consisting of alcohols, surfactants, antimicrobial agents, humectants, and cosmetic fats and oils. Preferably, such an anti-norovirus composition contains 0.01% to 5% by weight persimmon extract (in terms of solid content) based on the total composition.</p><p id="p0014" num="0014">Preferably, the anti-norovirus composition further contains an organic acid and/or a salt thereof. The organic acid and/or a salt thereof is preferably an organic acid having 2 to 10 carbon atoms and/or a salt thereof, more preferably a hydroxy-containing organic acid having 2 to 10 carbon atoms and/or a salt thereof. Among others, at least one organic acid selected from the group consisting of lactic<!-- EPO <DP n="8"> --> acid, malic acid, citric acid, tartaric acid, and salicylic acid and/or a salt thereof, particularly citric acid or a salt thereof is preferred.</p><p id="p0015" num="0015">Preferably, the anti-norovirus composition further contains vitamin C.</p><p id="p0016" num="0016">An alcohol used as a component of the anti-norovirus composition is preferably ethanol and/or isopropanol. An anti-norovirus composition according to one aspect of the present invention is provided as an anti-norovirus alcohol preparation that contains at least the anti-norovirus agent and an alcohol.</p><p id="p0017" num="0017">A surfactant used as a component of the anti-norovirus composition is preferably an anionic surfactant and/or a nonionic surfactant, more preferably at least one surfactant selected from the group consisting of glycerin fatty acid partial esters, sorbitan fatty acid partial esters, and sucrose fatty acid partial esters. An anti-norovirus composition according to one aspect of the present invention is provided as an anti-norovirus washing composition that contains at least the anti-norovirus agent and a surfactant.</p><p id="p0018" num="0018"><!-- EPO <DP n="9"> --> An antimicrobial agent used as a component of the anti-norovirus composition is preferably at least one synthetic antimicrobial agent selected from the group consisting of isopropylmethylphenol, butyl p-hydroxybenzoate, and triclosan. An anti-norovirus composition according to one aspect of the present invention is provided as an anti-norovirus disinfectant composition that contains at least the anti-norovirus agent and an antimicrobial agent.</p><p id="p0019" num="0019">A humectant used as a component of the anti-norovirus composition is preferably an aloe extract, and the cosmetic fat and oil is preferably beeswax. An anti-norovirus composition according to one aspect of the present invention is provided as a lotion, a milky lotion, or a cream that contains at least the anti-norovirus agent, a humectant, and/or a cosmetic fat and oil.</p><p id="p0020" num="0020">An anti-norovirus agent according to the present invention can also be used as an active ingredient of a therapeutic or prophylactic agent for an infectious disease caused by the norovirus. Thus, a therapeutic or prophylactic agent for an infectious disease caused by the norovirus according to the present invention is characterized by containing the anti-norovirus agent as an active ingredient.<!-- EPO <DP n="10"> --></p><heading id="h0006">Advantageous Effects of Invention</heading><p id="p0021" num="0021">A persimmon extract used as an anti-norovirus agent according to the present invention has much more excellent anti-norovirus characteristics than conventional bactericides; for example, the persimmon extract can kill 99% or more of norovirus. Such an anti-norovirus agent is not only directly used alone for disinfection or infection control against the norovirus, but also very useful as an active ingredient of a composition, such as an alcohol preparation, a washing composition, a hand soap, a disinfectant composition, a lotion, a milky lotion, or a cream, or a pharmaceutical agent for the norovirus.</p><p id="p0022" num="0022">Since a persimmon extract (persimmon tannin) is approved as a food additive, all the components of an anti-norovirus composition according to the present invention can be composed of food or food additives to produce a composition that causes no problem even if the composition adhering to food or dishes is ate or drunk. Use of an anti-norovirus composition according to the present invention that contains such a persimmon extract as an active ingredient allows efficient disinfection and infection control against the norovirus under circumstances where food is handled or in<!-- EPO <DP n="11"> --> medical institutions, holding promise of greatly decreasing the incidence of diseases caused by the norovirus (food poisoning).</p><p id="p0023" num="0023">In a conventional anti-norovirus characteristics test, a feline calicivirus has been used as an alternative (see <patcit id="pcit0008" dnum="JP2007045732A"><text>JP 2007-045732 A</text></patcit>). The feline calicivirus also belongs to <i>Caliciviridae</i>, is established as a cultured cell line, and has no ability to infect human. However, a feline calicivirus infects the lungs or bronchi, whereas the norovirus infects the intestinal tract. Even if a substance is effective for a feline calicivirus in the test, therefore, it is unclear whether the substance is also effective for the norovirus.</p><p id="p0024" num="0024">As described in the examples described below, real-time PCR using a norovirus showed that an anti-norovirus agent and an anti-norovirus composition according to the present invention have remarkable effects of not only eliminating the infectivity and proliferative capacity of the norovirus, but also killing the norovirus (eliminates the RNA of the norovirus). Thus, an anti-norovirus agent and an anti-norovirus composition according to the present invention are much more efficacious than conventional substances having<!-- EPO <DP n="12"> --> potential efficacy for a virus.</p><heading id="h0007">Brief Description of Drawings</heading><p id="p0025" num="0025"><ul><li>[<figref idrefs="f0001">Fig. 1</figref>] (a) to (c) are schematic views illustrating the state of virus when a sample acts on a norovirus. (a) shows that both the viral genome and the surface protein are normal, and the virus remains infectious (inefficacious). (b) shows that the viral genome remains but the surface protein is destroyed, and the virus lost infectivity (efficacious). (c) shows that both the viral genome and the surface protein are destroyed, and the virus lost infectivity (efficacious).</li><li>[<figref idrefs="f0001">Fig. 2] Fig. 2</figref> is a graph showing the results of a norovirus inactivation test of hand-washing foaming agents and a hand lotion in Example 2.</li><li>[<figref idrefs="f0002">Fig. 3] Fig. 3</figref> is a graph showing the results of an anti-norovirus activity stabilization test of a hand-washing foaming agent and a hand lotion with vitamin C in Example 3[1].</li><li>[<figref idrefs="f0002">Fig. 4] Fig. 4</figref> is a graph showing the results of an anti-norovirus activity stabilization test using vitamin C in Example 3[2].<!-- EPO <DP n="13"> --></li><li>[<figref idrefs="f0003">Fig. 5] Fig. 5</figref> is a graph showing the results of a synergistic effect test of the anti-norovirus activity using citric acid in Example 4.</li></ul></p><heading id="h0008">Best Modes for Carrying Out the Invention</heading><p id="p0026" num="0026">The term "anti-norovirus characteristics (activity)", as used herein, refers to the properties of inactivating (that is, "disinfecting") a norovirus, including killing a norovirus (see <figref idrefs="f0001">Fig. 1(c)</figref>) and acting on the surface protein to eliminate the infectivity (proliferative capacity) of a norovirus, although the norovirus survives (see <figref idrefs="f0001">Fig. 1(b)</figref>).</p><heading id="h0009"><u>Anti-norovirus Agent</u></heading><heading id="h0010">Persimmon Extract</heading><p id="p0027" num="0027">An anti-norovirus agent according to the present invention contains, as an active ingredient for anti-norovirus characteristics, an extract from a plant of the genus <i>Diospyros</i> containing tannin, that is, a persimmon extract (also referred to as a persimmon tannin). In addition to a substance derived from a plant of the genus <i>Diospyros</i> containing tannin, the persimmon extract may further contain a solvent used for extracting the substance.</p><p id="p0028" num="0028"><!-- EPO <DP n="14"> --> Use of an immature fruit of an astringent persimmon (such as <i>Diospyros kaki</i> Hachiya and Hiratanenashi) rich in persimmon tannin (particularly condensed tannin) is efficient and economical. A portion of a plant of the genus <i>Diospyros</i> other than fruit, such as leaves or bark, may be used as a raw material, provided that a persimmon extract composed of the same components can be produced.</p><p id="p0029" num="0029">Examples of a method for preparing a persimmon extract from such a raw material include a method in which an astringent persimmon from which a calyx is removed is ground and squeezed to recover squeezed juice, a method in which an astringent persimmon from which a calyx is removed is cut into a suitable size, is processed into a liquid with a blender, and is centrifuged to recover the supernatant liquid, and a method for recovering an extract using water or an aqueous solvent from an astringent persimmon from which a calyx is removed.</p><heading id="h0011">Heating, Alcohol Treatment, and Other Treatments</heading><p id="p0030" num="0030">Although squeezed juice or an extract from the fruit of a plant of the genus <i>Diospyros</i> can be directly used as a<!-- EPO <DP n="15"> --> persimmon extract according to the present invention, the squeezed juice or the extract is preferably treated by heating or with an alcohol (hereinafter also referred to as a "treated persimmon extract"). Heating or alcohol treatment can further improve the anti-norovirus characteristics of a persimmon extract and prevent the verification measurement of anti-norovirus characteristics from being interfered. Such a treated persimmon extract has the advantages of being relatively easily prepared and substantially free from color and odor issues when used as a component of the composition. A treated persimmon extract is therefore industrially easier to use than the astringent juice of the persimmon (described below), which takes time to ferment and is difficult to use in terms of color and odor.</p><p id="p0031" num="0031">The temperature and time conditions of the heat treatment may be such that an enzyme derived from a plant of the genus <i>Diospyros</i> contained in squeezed juice or an extract can be inactivated and may be general conditions under which the enzyme can be inactivated. More specifically, the heat treatment may be generally performed at a temperature in the range of 60°C to 130°C for a time period in the range of 5 seconds to 30 minutes, for example, at 120°C to 130°C for 5 to 10 seconds or at approximately 85°C for 5 to 15 minutes.<!-- EPO <DP n="16"> --> Examples of the heat-treatment process include heating in a process for sterilizing squeezed juice, heating in a powdering process, and heating before fermentation for producing the astringent juice of the persimmon (described in detail below).</p><p id="p0032" num="0032">The alcohol treatment may be performed with 30% to 100%, preferably 50% to 100%, alcohol, such as ethanol. For example, persimmon juice is treated with substantially the same amount of 95 v/v% ethanol, and the persimmon juice is preferably preserved in an airtight light-resistant container (usually resulting in a light-brown solution). Typically, as a process for producing an alcohol preparation as an anti-norovirus composition according to the present invention, an alcohol treatment process can be performed by adding an alcohol to a persimmon extract, which is, if necessary, heat-treated as described above. Such an alcohol treatment also has a sterilization effect on saprophytic bacteria in a persimmon extract.</p><p id="p0033" num="0033">Alternatively, or in addition, a persimmon extract<!-- EPO <DP n="17"> --> according to the present invention may be subjected to concentration, solidification by drying or lyophilization and powdering by grinding (the color of a lyophilized powder is generally light yellow), or purification using an ionexchange resin, if necessary, without compromising the advantages of the present invention. Since a persimmon extract contains much polyphenol, a liquid persimmon extract is liable to undergo deterioration, such as coloring. A persimmon extract is therefore preferably preserved in a solid state in frozen storage by lyophilization. Preferably, these procedures are performed under mild conditions such that persimmon tannin and other components in a persimmon extract are not decomposed.</p><p id="p0034" num="0034">A persimmon extract in the present invention may be "the astringent juice of the persimmon" which is a liquid produced by fermenting and aging squeezed juice of an immature astringent persimmon for a long period of time (approximately 1 to 3 years) and contains several percent solid (persimmon tannin) and an organic acid produced by the fermentation. The astringent juice of the persimmon has been used as folk medicine or a paint and is commercially available as a commodity, such as "Kakisibu" (Toyama Kakisibu Seizojo). Alternatively, a fermented product prepared by adding a yeast<!-- EPO <DP n="18"> --> culture solution derived from a persimmon to persimmon juice and fermenting it at a temperature in the range of 20°C to 25°C for 1 to 3 months may be used (a reddish-brown liquid is usually produced). Preferably, the fermented product is preserved in an airtight container.</p><p id="p0035" num="0035">An additive described as "persimmon tannin" (Name/Synonym = The astringent juice of the persimmon, a persimmon extract. Origin/Preparation/Nature = Squeezed juice of the fruit of <i>Diospyros kaki</i> THUNB., or a water or ethanol extract. The main component is tannin and tannic acid.) in "List of Existing Food Additives" based on the Food Sanitation Act in Japan may also be used as a persimmon extract in the present invention.</p><heading id="h0012">Persimmon Tannin</heading><p id="p0036" num="0036">A plant of the genus <i>Diospyros,</i> particularly its fruit, is rich in substances having certain properties, such as astringency and affinity for metal ions, and responsible for astringency, that is, compounds collectively referred to as tannin. In many instances, persimmon tannin characteristically contains, as a major component, "persimmon condensed tannin" having the following probable structural formula (I), which is composed of catechin, gallocatechin,<!-- EPO <DP n="19"> --> and gallic acid esters thereof. For example, persimmon condensed tannin contained in the fruit of <i>Diospyros kaki,</i> which is a plant of the genus <i>Diospyros</i> native to China and is cultivated worldwide, including Japan, is a high-molecular compound in which catechin, catechin gallate, gallocatechin, and gallocatechin gallate are condensed via carbon-carbon bonds at a ratio of approximately 1:1:2:2 (Matsuo &amp; Itoo (1981): see Non-patent Literature 1 cited above).
<chemistry id="chem0001" num="0001"><img id="ib0001" file="imgb0001.tif" wi="148" he="53" img-content="chem" img-format="tif"/></chemistry></p><p id="p0037" num="0037">In addition to the "persimmon condensed tannin" described above, persimmon tannin sometimes contains another tannin compound, such as catechin or hydrolyzable tannin.</p><p id="p0038" num="0038">Hydrolyzable tannin is an ester between an alcohol (such as glucose) and a carboxylic acid (such as gallic acid) or an oligomer thereof and is depolymerized by hydrolysis. In contrast, persimmon condensed tannin is not depolymerized by<!-- EPO <DP n="20"> --> hydrolysis (the basic carbon-carbon skeleton of the polymer is not hydrolyzed). Persimmon condensed tannin can therefore be differentiated from hydrolyzable tannin and can be purified and quantified, for example, by a method described in Matsuo &amp; Itoo (1981b) (Non-patent Literature 2 cited above).</p><p id="p0039" num="0039">Comparative test results in the examples described below showed that tannin that is not derived from a plant of the genus <i>Diospyros,</i> for example, gallnut tannic acid (hydrolyzable tannin) derived from sumac, wattle tannin derived from acacia or mimosa, catechin, gallic acid, or propyl gallate (gallic acid propyl ester) independently had no efficacy for a norovirus. To develop anti-norovirus characteristics in the present invention, although it is assumed that a persimmon extract preferably contains at least persimmon condensed tannin, possible contribution of another component in the persimmon extract is not excluded. In general, a persimmon extract prepared by a method described below using the fruit of <i>Diospyros kaki</i> spontaneously contains persimmon condensed tannin. Thus, it is assumed that an anti-norovirus agent according to the present invention is preferably produced using such a persimmon extract as a raw material.<!-- EPO <DP n="21"> --></p><heading id="h0013">Anti-norovirus Composition</heading><p id="p0040" num="0040">An anti-norovirus composition according to the present invention contains an anti-norovirus agent as an active ingredient for the norovirus and at least one component selected from the group consisting of alcohols, surfactants, antimicrobial agents, humectants, and cosmetic fats and oils and, if necessary, further contains an organic acid, such as citric acid, and/or a salt thereof, or vitamin C. Representative aspects are as follows:</p><p id="p0041" num="0041"><ul><li>An alcohol preparation that contains at least an anti-norovirus agent and an alcohol.</li><li>A washing composition that contains at least an anti-norovirus agent and a surfactant.</li><li>A disinfectant composition that contains at least an anti-norovirus agent and an antimicrobial agent.</li><li>A lotion, a milky lotion, or a cream that contains at least an anti-norovirus agent and a humectant and/or a cosmetic fat and oil.</li></ul></p><p id="p0042" num="0042">A washing composition according to one aspect of the present invention can remove contamination of food, dishes,<!-- EPO <DP n="22"> --> cooking utensils, fingers of workers, and clothes and kill the norovirus. For example, the washing composition is provided as a liquid or solid detergent. An alcohol preparation and a disinfectant composition according to other aspects of the present invention are used to inactivate the norovirus and bacteria deposited on food, dishes, cooking utensils, fingers of workers, and instruments with which the excreta of patients infected with the norovirus are treated. For example, like conventional ethanol preparations, the alcohol preparation and the disinfectant composition are provided as sprays. A lotion, a cream, and a milky lotion according to still other aspects of the present invention are applied to fingers of workers that tend to be chapped from washing to improve the condition of the skin and can kill the norovirus (skin-care preparations).</p><p id="p0043" num="0043">It goes without saying that an alcohol, a surfactant, an antimicrobial agent, a humectant, and a cosmetic fat and oil may be used in combination in an anti-norovirus composition according to the present invention. For example, an alcohol preparation preferably further contains a surfactant, such as a fatty acid ester, to improve antimicrobial properties. According to other aspects of the present invention, the washing composition can be a hand soap that contains an<!-- EPO <DP n="23"> --> antimicrobial agent or an alcohol, as well as a surfactant, and the cream can contain an antimicrobial agent or an alcohol for keeping the skin clean, as well as a component for protecting the skin.</p><p id="p0044" num="0044">In addition to the components specifically described herein, an anti-norovirus composition according to the present invention may appropriately contain a component for imparting a desired capability to improve the quality of the composition, for example, a thickener (such as xanthan, locust bean gum, or sodium polyacrylate), an antioxidant, a perfume, and/or a dye, and cosmetics, such as a lotion, may appropriately contain a barrier cream and/or an antiphlogistic agent.</p><heading id="h0014">Amount of Anti-norovirus Agent</heading><p id="p0045" num="0045">The amount of anti-norovirus agent in an anti-norovirus composition according to the present invention can be appropriately adjusted in a manner that depends on the component ratios of the composition and a method for using the composition, provided that the composition has anti-norovirus characteristics, and may be such that the amount of persimmon extract in the anti-norovirus agent preferably ranges from 0.01% to 5% by weight, more preferably 0.1% to 2%<!-- EPO <DP n="24"> --> by weight, still more preferably 0.2% to 2% by weight, most preferably 0.5% to 2% by weight, of the total amount of anti-norovirus composition.</p><p id="p0046" num="0046">The amount of persimmon extract is based on a "solid". For example, when a liquid substance, such as a persimmon fruit extract, is used as a raw material, the amount of the liquid substance is controlled such that the weight of a solid (a powder produced by drying or lyophilization) in the liquid substance is in the range described above. In general, squeezed juice of a persimmon fruit contains approximately 5% to 10% solid.</p><heading id="h0015">Organic Acid and/or Salt Thereof</heading><p id="p0047" num="0047">In addition to the anti-norovirus agent described above, an anti-norovirus composition according to the present invention preferably contains an organic acid and/or a salt thereof. The organic acid and/or a salt thereof is preferably an organic acid having 2 to 10 carbon atoms and/or a salt thereof, more preferably a hydroxy-containing organic acid having 2 to 10 carbon atoms and/or a salt thereof, for example, lactic acid, malic acid, citric acid, tartaric acid, salicylic acid, maleic acid, fumaric acid, succinic acid, and/or a salt thereof. Among others, at least one organic<!-- EPO <DP n="25"> --> acid selected from the group consisting of lactic acid, malic acid, citric acid, tartaric acid, and salicylic acid and/or a salt thereof, particularly citric acid or a salt thereof is preferred. A salt of an organic acid is preferably a sodium or potassium salt of the organic acid described above (for example, trisodium citrate). An organic acid, such as citric acid, and/or a salt thereof independently has no anti-norovirus characteristics. However, in combination with a persimmon extract, the organic acid and/or a salt thereof can further increase the efficacy of the persimmon extract. Citric acid and/or a salt thereof also has antimicrobial activity against bacteria, is approved as a food additive, and functions as a chelating agent for preventing coloring of a persimmon extract (persimmon tannin) in contact with iron.</p><p id="p0048" num="0048">The amount of the organic acid and/or a salt thereof described above preferably ranges from 0.05% to 5.0% by weight, more preferably 0.1% to 2.0% by weight, of the total amount of anti-norovirus composition (including solvent). When an organic acid and/or a salt thereof is used for an aqueous composition, the amount of organic acid and/or salt thereof is preferably such that the pH ranges from 2 to 6.</p><heading id="h0016">Vitamin C</heading><!-- EPO <DP n="26"> --><p id="p0049" num="0049">In addition to the anti-norovirus agent described above, an anti-norovirus composition according to the present invention preferably contains vitamin C, which is known as an antioxidant to be added to food. "Vitamin C" is a generic name and includes DL-ascorbic acid and ascorbic acid esters (such as palmitate), as well as L-ascorbic acid, which is generally referred to as vitamin C. Vitamin C can prevent oxidation of a persimmon extract (particularly persimmon tannin), ensure stable and persistent efficacy against the norovirus, and prevent reddening due to oxidation.</p><p id="p0050" num="0050">The amount of vitamin C preferably ranges from 0.01% to 3.0% by weight, more preferably 0.05% to 1.0% by weight, of the total amount of anti-norovirus composition (including solvent).</p><heading id="h0017">Alcohol</heading><p id="p0051" num="0051">The alcohol may be an alcohol used in general alcohol preparations and is preferably ethanol and/or propanol, which has an excellent antimicrobial activity against bacteria and is approved as a food additive. The concentration of the alcohol may be substantially the same as in general alcohol preparations, can be adjusted in consideration of antimicrobial activity, and preferably ranges from<!-- EPO <DP n="27"> --> approximately 20% to 80% of the total amount of alcohol preparation. An alcohol may be used as a solvent in a composition other than alcohol preparations and may be contained in cosmetics as a component for imparting astringency to the skin or an antiseptic property.</p><heading id="h0018">Surfactant</heading><p id="p0052" num="0052">Surfactants include cationic, anionic, amphoteric, and nonionic surfactants. Taking the chemical properties of persimmon condensed tannin (polyphenol) into account, an anionic surfactant and/or a nonionic surfactant is preferably used in the present invention.</p><p id="p0053" num="0053">Examples of the anionic surfactant include soap (alkali salts of higher fatty acids), monoalkyl sulfates, alkyl polyoxyethylene sulfates, alkylbenzene sulfonates, and monoalkyl phosphates.</p><p id="p0054" num="0054">Examples of the nonionic surfactant include polyoxyethylene alkyl ethers, polyoxyethylene fatty acid esters, fatty acid partial esters of polyhydric alcohols (such as glycerin and sugar alcohol), and fatty acid diethanolamides.</p><p id="p0055" num="0055"><!-- EPO <DP n="28"> --> Among these surfactants, surfactants approved as food additives, such as glycerin fatty acid partial esters, sorbitan fatty acid partial esters, and sucrose fatty acid partial esters, are preferred in the present invention because these surfactants present no problem even if they are deposited on food, dishes, or cooking utensils.</p><p id="p0056" num="0056">The surfactants also destroy cell membranes of bacteria or envelopes of viruses. For example, partial esters of glycerin and fatty acids having 6 to 18 carbon atoms have high antimicrobial activity against <i>Escherichia coli</i> and <i>Staphylococcus aureus</i>. Thus, the alcohol preparation preferably contains such a surfactant. The surfactants are also used to mix an oil phase and an aqueous phase in creams and milky lotions.</p><heading id="h0019">Antimicrobial Agent</heading><p id="p0057" num="0057">Antimicrobial agents (including substances called bactericides and disinfectants) for use in the present invention, other than ethanol and citric acid described above, include antimicrobial agents that are efficacious against <i>Escherichia coli, Staphylococcus aureus</i>, MRSA, Salmonella, <i>Vibrio parahaemolyticus</i>, or <i>Pseudomonas<!-- EPO <DP n="29"> --> aeruginosa</i>, which, like the norovirus, causes problems of infection in food processing or nosocomial infection. Examples of such antimicrobial agents are as follows:
<ul><li>Natural antimicrobial agents: proteins (such as milt protein and egg-white lysozyme) and peptides (such as polylysine);</li><li>Antibiotics: penicillin antibiotics, chloramphenicol, streptomycin, tetracycline antibiotics, and cephalosporin antibiotics; and</li><li>Synthetic antimicrobial agents: chlorine compounds (such as triclosan), iodine compounds (such as povidone-iodine), zinc compounds (such as zinc cetylpyridinium), benzenecarboxylic acids (such as benzoic acid, salicylic acid, isopropylmethylphenol, and butyl p-hydroxybenzoate (= butylparaben)), organic acid esters (such as glycerin esters and sucrose esters), aldehydes (such as glutaraldehyde and formaldehyde), biguanide compounds (such as chlorhexidine gluconate), and quaternary ammonium salts (such as benzalkonium chloride and cetylammonium bromide).</li></ul></p><p id="p0058" num="0058">Among these antimicrobial agents, isopropylmethylphenol, butyl p-hydroxybenzoate, and triclosan are preferred in the present invention because of strong antimicrobial action and high compatibility with a persimmon extract.<!-- EPO <DP n="30"> --></p><p id="p0059" num="0059">A substance that can be used as an antimicrobial agent as described above may be contained in the ethanol preparation described above and is sometimes used as an antiseptic in cosmetics.</p><heading id="h0020">Humectant</heading><p id="p0060" num="0060">Humectants (wetting agents) that can be used in the present invention are those used in cosmetics such as, general lotions, milky lotions, and creams, and include glycerin, propylene glycol, sorbitol, polyethylene glycol, hyaluronic acid, sodium chondroitin sulfate, ceramide, and an aloe extract. Among these humectants, humectants approved as food or food additives, such as an aloe extract, are preferred in the present invention because they cause no problem even if they adheres to food, dishes, or cooking utensils.</p><heading id="h0021">Cosmetic Fats and Oils</heading><p id="p0061" num="0061">Cosmetic fats and oils form a film on the skin to protect the skin and impart flexibility, smoothness, and gloss to the skin. Cosmetic fats and oils also impart moderate availability to cosmetics. In the present invention, cosmetic fats and oils used in cosmetics, such as general<!-- EPO <DP n="31"> --> milky lotions and creams, can be used. Examples of the cosmetic fats and oils are as follows:</p><p id="p0062" num="0062"><ul><li>Fats and oils (esters of higher fatty acids and glycerin): vegetable oils and fats, animal oils and fats, hydrogenated compounds thereof (such as partially hydrogenated rapeseed oil), and synthetic triglyceride (such as tri(capryl/capric acid)glyceryl);</li><li>Wax (esters of higher fatty acids and higher alcohols, the esters being solid at normal temperature): vegetable wax and animal wax (such as beeswax and lanolin);</li><li>Hydrocarbons: mineral hydrocarbons (such as liquid paraffin, vaseline, and paraffin) and animal hydrocarbons (such as squalane);</li><li>Higher fatty acids: lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, and isostearic acid;</li><li>Higher alcohols: cetanol, stearyl alcohol, and lanolin alcohol; and</li><li>Esters (esters of fatty acids and alcohols other than wax): myristyl myristate, propylene glycol dioleate, and cetyl lactate.</li></ul></p><p id="p0063" num="0063">Among these, cosmetic fats and oils approved as food or food additives, such as beeswax, are preferred in the present<!-- EPO <DP n="32"> --> invention because these cosmetic fats and oils cause no problem even if they adheres to food, dishes, or cooking utensils.</p><heading id="h0022">Manufacturing Method</heading><p id="p0064" num="0064">A method for manufacturing an anti-norovirus composition according to the present invention is the same as a method for manufacturing a conventional alcohol preparation, detergent, disinfectant, lotion, milky lotion, or cream, except that an anti-norovirus agent (a persimmon extract) is contained as a raw material and, if necessary, an organic acid, such as citric acid, and/or a salt thereof or vitamin C is contained, and accordingly additional adjustments are appropriately made. An anti-norovirus composition according to the present invention can be produced using an anti-norovirus agent, in addition to general (or, if necessary, finely adjusted) raw materials of these conventional products by the same (or, if necessary, finely adjusted) manufacturing process as that for conventional products. For example, a cream according to one aspect of the present invention may be produced by adding an anti-norovirus agent and other components to purified water to prepare an aqueous phase, preparing an oil phase composed of a cosmetic fat and oil and other materials, and mixing the aqueous phase and the oil<!-- EPO <DP n="33"> --> phase at a predetermined ratio.</p><p id="p0065" num="0065">A method for using an anti-norovirus composition according to the present invention is also the same as a method for using a conventional alcohol preparation, detergent, disinfectant, lotion, milky lotion, or cream. An anti-norovirus composition according to the present invention can be commercialized in accordance with a suitable aspect depending on a method for using the anti-norovirus composition. For example, a detergent may be a concentrated detergent, which is diluted before use; and an alcohol preparation or a disinfectant may be of a spray type or a wiper in which a nonwoven fabric is impregnated with the alcohol preparation or the disinfectant.</p><heading id="h0023">Pharmaceutical Agent</heading><p id="p0066" num="0066">An anti-norovirus agent according to the present invention can be used as an active ingredient of a therapeutic or prophylactic agent for an infectious disease caused by the norovirus. The dosage form of such a pharmaceutical agent can be appropriately selected from, for example, oral ingestion forms, such as a liquid, a syrup, a tablet, a capsule, a powder, and granules, and an injection, and can be produced by a general preparation method, if<!-- EPO <DP n="34"> --> necessary, in combination with various additive agents, such as an excipient (for example, lactose or another saccharide), a binder (for example, starch, methylcellulose, or poly(vinyl alcohol)), a stabilizer (for example, ascorbic acid), a preservative (for example, p-hydroxybenzoate), a sweetener, and/or a solvent. The effective dose of such a pharmaceutical agent can be appropriately determined in accordance with the age, the body weight, and the symptom of a patient, the administration route, the administration schedule, and the formulation of the pharmaceutical agent, and the inhibitory activity of materials. The amount of anti-norovirus agent in a pharmaceutical agent may be adjusted to these conditions.</p><heading id="h0024">EXAMPLES</heading><heading id="h0025">Norovirus Test Solution</heading><p id="p0067" num="0067">A frozen stock solution of a norovirus isolated from stools of a patient and cryopreserved at -80°C was thawed on ice. A hundred microliters of the norovirus stock solution was diluted ten times with phosphate-buffered saline (PBS) and was spun in a refrigerated centrifuge at 10,000 rpm for 20 minutes to remove a precipitate. The resulting "norovirus test solution" (950 µL solution) was used in the following<!-- EPO <DP n="35"> --> examples.</p><heading id="h0026">Real-time PCR</heading><p id="p0068" num="0068">The "real-time PCR" in the following examples was performed in accordance with a document "<nplcit id="ncit0003" npl-type="s" url="http://www.mhlw.go.jp/topics/syokuchu/kanren/kanshi/031105-1.html"><text>Detection Method for Norovirus" attached to a notice (Notice No. 1105001 from the Inspection and Safety Division, dated November 5, 2003. See http://www.mhlw.go.jp/topics/syokuchu/kanren/kanshi/031105-1.html</text></nplcit>) issued by the Director of the Inspection and Safety Division, Department of Food Safety, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare.</p><p id="p0069" num="0069">The real-time PCR counts the number of viral genomes in the states of (a) and (b) in <figref idrefs="f0001">Fig. 1</figref>. In the following examples, only elimination of (the RNA of) a norovirus illustrated in (c) is rated as "efficacious", and the survival of (the RNA of) a norovirus illustrated in (b) is rated as "inefficacious" even if the infectivity and proliferative capacity of the norovirus are lost. Nevertheless, an anti-norovirus composition according to the present invention is rated as more efficacious than conventional compositions. Taking the state of a norovirus illustrated in (b) into account, an anti-norovirus composition according to the present invention should<!-- EPO <DP n="36"> --> therefore have still higher practical efficacy.</p><heading id="h0027">[EXAMPLE 1]</heading><heading id="h0028">Preparation of Persimmon Extract and Ethanol Preparation</heading><p id="p0070" num="0070"><ol><li>(a) Persimmon tannin fermented liquid (FA-1): a ground product of an immature fruit of <i>Diospyros kaki</i> (astringent persimmon) was charged in a fine-weave cloth bag and was squeezed. The squeezed juice was charged in a glass vessel and was naturally fermented for approximately one year. A solid was then filtered off to prepare a reddish-brown solution. The solution contained approximately 10% solid component (a persimmon extract), and approximately half (approximately 5%) of the solid component was persimmon tannin.</li><li>(b) A persimmon tannin lyophilized powder (FD-1): a ground product of an immature fruit of <i>Diospyros kaki</i> (astringent persimmon) was charged in a fine-weave cloth bag and was squeezed. The squeezed juice was lyophilized to prepare a powder. Although the yield of the powder fluctuated because it was a natural product, the yield ranged from approximately 5% to 7%.</li></ol></p><p id="p0071" num="0071">The persimmon extracts (FA-1 and FD-1), ethanol, citric<!-- EPO <DP n="37"> --> acid, and trisodium citrate were used to prepare the compositions (ethanol preparations) A1 to A4 listed in Table 1. Samples containing components other than the persimmon extracts were used to prepare the sample solutions B1 to B7 listed in Table 1.</p><heading id="h0029">Anti-norovirus Characteristics Test</heading><p id="p0072" num="0072">Twenty-five microliters of the norovirus test solution and 25 µL of each of the compositions (A1 to A5 or B1 to B7) were sufficiently mixed. The liquid mixture was left stand at room temperature for 2 minutes and was then diluted 50 times with PBS. After the diluted solution was subjected to treatments, such as RNA extraction and cDNA synthesis, viral genome RNAs remaining in the diluted solution was counted by real-time PCR. Controls for each of the sample solutions were also tested in the same manner. These measured values for the sample solutions and the corresponding controls were compared to determine the inhibition rates of the compositions for the norovirus.</p><p id="p0073" num="0073">Table 1 shows the results. The compositions A1 to A4 containing the persimmon extract (FD-1 or FA-1) had a markedly high inhibition rate than the composition B1 containing povidone-iodine, which is a conventional general-purpose<!-- EPO <DP n="38"> --> antimicrobial agent having anti-norovirus action. The compositions containing hydrolyzable tannin, low-molecular tannin, or an analogous compound thereof had no efficacy against the norovirus.</p><p id="p0074" num="0074">In the description of the following examples (including tables), unless otherwise specified, "%" represents "% by weight".</p><p id="p0075" num="0075">[Table 1]
<tables id="tabl0001" num="0001"><table frame="all"><title>Table 1 Component Ratios of Compositions and Anti-norovirus Characteristics Test Results</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="19mm"/><colspec colnum="2" colname="col2" colwidth="43mm"/><colspec colnum="3" colname="col3" colwidth="20mm"/><colspec colnum="4" colname="col4" colwidth="19mm"/><colspec colnum="5" colname="col5" colwidth="29mm"/><colspec colnum="6" colname="col6" colwidth="24mm"/><thead><row><entry rowsep="0" valign="top"/><entry namest="col2" nameend="col5" align="center" valign="top">Components of sample solution (the remainder is water)</entry><entry morerows="1" align="center" valign="top">Inhibition rate</entry></row><row><entry valign="top"/><entry align="center" valign="top">Persimmon extract/Control</entry><entry align="center" valign="top">Ethanol</entry><entry align="center" valign="top">Citric acid</entry><entry align="center" valign="top">Trisodium citrate</entry></row></thead><tbody><row><entry align="center">A1</entry><entry>FA-1 0.5%</entry><entry align="center">50%</entry><entry align="center">1.6%</entry><entry align="center">0.5%</entry><entry align="center">98%</entry></row><row><entry align="center">A2</entry><entry>FD-1 0.5%</entry><entry align="center">50%</entry><entry align="center">1.6%</entry><entry align="center">0.5%</entry><entry align="center">99%</entry></row><row><entry align="center">A3</entry><entry>FD-1 0.5%</entry><entry align="center">50%</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">93%</entry></row><row><entry align="center">A4</entry><entry>FD-1 0.2%</entry><entry align="center">50%</entry><entry align="center">1.6%</entry><entry align="center">0.5%</entry><entry align="center">86%</entry></row><row><entry align="center">B1</entry><entry>Povidone-iodine 0.1%</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">45%</entry></row><row><entry align="center">B2</entry><entry>Tannic acid<sup>*1</sup> 0.5%</entry><entry align="center">50%</entry><entry align="center">1.6%</entry><entry align="center">0.5%</entry><entry align="center">0%</entry></row><row><entry align="center">B3</entry><entry>Wattle tannin<sup>*2</sup> 1%</entry><entry align="center">50%</entry><entry align="center">1.6%</entry><entry align="center">0.5%</entry><entry align="center">0%</entry></row><row><entry align="center">B4</entry><entry>Propyl gallate 1%</entry><entry align="center">50%</entry><entry align="center">1.6%</entry><entry align="center">0.5%</entry><entry align="center">0%</entry></row><row><entry align="center">B5</entry><entry>Catechin 1%</entry><entry align="center">50%</entry><entry align="center">1.6%</entry><entry align="center">0.5%</entry><entry align="center">0%</entry></row><row><entry align="center">B6</entry><entry>Gallic acid 1%</entry><entry align="center">50%</entry><entry align="center">1.6%</entry><entry align="center">0.5%</entry><entry align="center">0%</entry></row><row><entry align="center">B7</entry><entry>Pyrogallol 1%</entry><entry align="center">50%</entry><entry align="center">1.6%</entry><entry align="center">0.5%</entry><entry align="center">0%</entry></row></tbody></tgroup><tgroup cols="6" rowsep="0"><colspec colnum="1" colname="col1" colwidth="19mm"/><colspec colnum="2" colname="col2" colwidth="43mm"/><colspec colnum="3" colname="col3" colwidth="20mm"/><colspec colnum="4" colname="col4" colwidth="19mm"/><colspec colnum="5" colname="col5" colwidth="29mm"/><colspec colnum="6" colname="col6" colwidth="24mm"/><tbody><row><entry namest="col1" nameend="col6" align="justify">*1 Tannic acid: Hydrolyzable tannin derived from sumac (gall). The main component is 1,2,3,4,6-pentagalloylglucose or a multimer thereof.<br/>
*2 Wattle tannin: Hydrolyzable tannin derived from acacia.<br/>
*3 Propyl gallate: Gallic acid propyl ester.</entry></row></tbody></tgroup></table></tables></p><heading id="h0030">Antimicrobial Test</heading><!-- EPO <DP n="39"> --><heading id="h0031">(1) Test Sample</heading><p id="p0076" num="0076">The persimmon extract (FD-1) prepared as described above, glycerin caproate, citric acid, trisodium citrate, and ethanol were used to prepare the compositions A5 to A7 listed in Table 2. The stock solutions of these compositions A5 to A7 and 2-, 4-, 8-, 16- and 20-fold diluted solutions of these compositions A5 to A7 diluted with purified water were used as test samples.</p><p id="p0077" num="0077">[Table 2]
<tables id="tabl0002" num="0002"><table frame="all"><title>Table 2 Component Ratios of Compositions (the remainder is water)</title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="30mm"/><colspec colnum="2" colname="col2" colwidth="24mm"/><colspec colnum="3" colname="col3" colwidth="24mm"/><colspec colnum="4" colname="col4" colwidth="24mm"/><thead><row><entry align="center" valign="top"/><entry align="center" valign="top">A5</entry><entry align="center" valign="top">A6</entry><entry align="center" valign="top">A7</entry></row></thead><tbody><row><entry>FD-1</entry><entry align="center">1%</entry><entry align="center">0.5%</entry><entry align="center">0.5%</entry></row><row><entry>Glycerin caproate</entry><entry align="center"/><entry align="center">0.5%</entry><entry align="center">0.5%</entry></row><row><entry>Citric acid</entry><entry align="center"/><entry align="center"/><entry align="center">1.6%</entry></row><row><entry>Trisodium citrate</entry><entry align="center"/><entry align="center"/><entry align="center">0.5%</entry></row><row><entry>Ethanol</entry><entry align="center">50%</entry><entry align="center">50%</entry><entry align="center">50%</entry></row></tbody></tgroup></table></tables></p><heading id="h0032">(2) Type of Bacteria</heading><p id="p0078" num="0078"><ul><li><i>Escherichia coli:</i> IF03301 strain</li><li>Staphylococcus aureus: IF012792 strain</li></ul></p><heading id="h0033">(3) Culture Media and Culture Conditions</heading><p id="p0079" num="0079"><ul><li><i>Escherichia coli</i>: cultured on desoxycholate agar at 35°C for 24 hours.</li><li><i>Staphylococcus aureus</i>: cultured on mannitol salt agar at 35°C for 48 hours</li></ul><!-- EPO <DP n="40"> --></p><heading id="h0034">(4) Procedures</heading><p id="p0080" num="0080">One milliliter of bacterial suspension was added to 9 mL of a test sample. The test sample was stirred and sensitized for 1 minute. The test sample was smeared on a selective medium. After an incubation period, bacterial proliferation was checked to rate the efficacy. Table 3 shows the results.</p><p id="p0081" num="0081"><tables id="tabl0003" num="0003"><table frame="all"><title>[Table 3] Table Antimicrobial Test Results</title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="38mm"/><colspec colnum="2" colname="col2" colwidth="24mm"/><colspec colnum="3" colname="col3" colwidth="33mm"/><colspec colnum="4" colname="col4" colwidth="33mm"/><colspec colnum="5" colname="col5" colwidth="33mm"/><thead><row><entry morerows="1" align="center" valign="top">Type of bacteria</entry><entry namest="col2" nameend="col5" align="center" valign="top">Dilution and bacterial count of sample</entry></row><row><entry align="center" valign="top">Dilution</entry><entry align="center" valign="top">Bacterial count of A5</entry><entry align="center" valign="top">Bacterial count of A6</entry><entry align="center" valign="top">Bacterial count of A7</entry></row></thead><tbody><row><entry morerows="6" align="center">Escherichia coli</entry><entry align="center">Control</entry><entry align="center">10<sup>7</sup></entry><entry align="center">10<sup>7</sup></entry><entry align="center">10<sup>7</sup></entry></row><row><entry align="center">Stock solution</entry><entry align="center">&lt;100</entry><entry align="center">&lt;100</entry><entry align="center">&lt;100</entry></row><row><entry align="center">2-fold</entry><entry align="center">2.5 x 10<sup>4</sup></entry><entry align="center">&lt;100</entry><entry align="center">&lt;100</entry></row><row><entry align="center">4-fold</entry><entry align="center">-</entry><entry align="center">&lt;100</entry><entry align="center">&lt;100</entry></row><row><entry align="center">8-fold</entry><entry align="center">-</entry><entry align="center">2.0 x 10<sup>2</sup></entry><entry align="center">&lt;100</entry></row><row><entry align="center">16-fold</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">&lt;100</entry></row><row><entry align="center">20-fold</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">&lt;100</entry></row><row><entry morerows="6" align="center">Staphylococcus aureus</entry><entry align="center">Control</entry><entry align="center">10<sup>7</sup></entry><entry align="center">10<sup>7</sup></entry><entry align="center">10<sup>7</sup></entry></row><row><entry align="center">Stock solution</entry><entry align="center">&lt;100</entry><entry align="center">&lt;100</entry><entry align="center">&lt;100</entry></row><row><entry align="center">2-fold</entry><entry align="center">-</entry><entry align="center">&lt;100</entry><entry align="center">&lt;100</entry></row><row><entry align="center">4-fold</entry><entry align="center">-</entry><entry align="center">4 x 10<sup>3</sup></entry><entry align="center">&lt;100</entry></row><row><entry align="center">8-fold</entry><entry align="center">-</entry><entry align="center">1 x 10<sup>4</sup></entry><entry align="center">&lt;100</entry></row><row><entry align="center">16-fold</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">&lt;100</entry></row><row><entry align="center">20-fold</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">6 x 10<sup>2</sup></entry></row></tbody></tgroup><tgroup cols="5" rowsep="0"><colspec colnum="1" colname="col1" colwidth="38mm"/><colspec colnum="2" colname="col2" colwidth="24mm"/><colspec colnum="3" colname="col3" colwidth="33mm"/><colspec colnum="4" colname="col4" colwidth="33mm"/><colspec colnum="5" colname="col5" colwidth="33mm"/><tbody><row><entry namest="col1" nameend="col5" align="justify">Note 1) "&lt;100" indicates no proliferation of bacteria (efficacious).<br/>
Note 2) "-" indicates infinite proliferation of bacteria (inefficacious).</entry></row></tbody></tgroup></table></tables></p><p id="p0082" num="0082">High antimicrobial activity in the order of A7 &gt; A6 &gt; A5 was observed for <i>Escherichia coli</i> and <i>Staphylococcus aureus</i>. These results show that the combination of ethanol, a fatty<!-- EPO <DP n="41"> --> acid ester, and an organic acid and a salt thereof yielded an anti-norovirus composition having efficacy against not only the norovirus but also bacteria, such as <i>Escherichia coli.</i></p><heading id="h0035">[EXAMPLE 2]</heading><heading id="h0036">[1] Preparation of Persimmon Extract, Hand-Washing Foaming Agent, and Hand Lotion</heading><p id="p0083" num="0083"><ul><li>(c) A persimmon extract (the astringent juice of the persimmon FD2-2): a fruit of persimmon after sufficient treatments, such as sterilization (NaClO), washing, and prevention of discoloration (vitamin C), was diced and mashed. The resulting solution of fruit and juice was passed through a 200-mesh sieve, was sterilized at a high temperature (120°C to 130°C for 7 to 10 seconds), and was freeze-dried to prepare a powdered persimmon extract (the astringent juice of the persimmon FD2-2).</li></ul></p><p id="p0084" num="0084">Components listed in the following Table 4 were mixed to prepare three hand-washing foaming agents containing the persimmon extract (FD2-2). Components listed in the following Table 5 were mixed to prepare a hand lotion containing the persimmon extract (FD2-2).</p><p id="p0085" num="0085"><!-- EPO <DP n="42"> --> [Table 4]
<tables id="tabl0004" num="0004"><table frame="all"><title>Table 4 Compositions of Hand-washing Foaming Agents (unit: g)</title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="56mm"/><colspec colnum="2" colname="col2" colwidth="19mm"/><colspec colnum="3" colname="col3" colwidth="19mm"/><colspec colnum="4" colname="col4" colwidth="19mm"/><thead><row><entry align="center" valign="top"/><entry align="center" valign="top">KSF15-1</entry><entry align="center" valign="top">KSF15-2</entry><entry align="center" valign="top">KSF15-3</entry></row></thead><tbody><row><entry>Isopropylmethylphenol</entry><entry align="char" char="." charoff="29">0.1</entry><entry align="char" char="." charoff="29">0.1</entry><entry align="char" char="." charoff="29">0.1</entry></row><row><entry>Astringent juice of persimmon FD2-2</entry><entry align="char" char="." charoff="29">0.5</entry><entry align="char" char="." charoff="29">0.5</entry><entry align="char" char="." charoff="29">0.5</entry></row><row><entry>95% ethanol</entry><entry align="char" char="." charoff="29">20.0</entry><entry align="char" char="." charoff="29">18.0</entry><entry align="char" char="." charoff="29">15.0</entry></row><row><entry>Mydol 12*1</entry><entry align="char" char="." charoff="29">7.0</entry><entry align="char" char="." charoff="29">7.0</entry><entry align="char" char="." charoff="29">7.0</entry></row><row><entry>Glycerin</entry><entry align="char" char="." charoff="29">15.0</entry><entry align="char" char="." charoff="29">15.0</entry><entry align="char" char="." charoff="29">13.0</entry></row><row><entry>Citric acid</entry><entry align="char" char="." charoff="29">1.0</entry><entry align="char" char="." charoff="29">1.0</entry><entry align="char" char="." charoff="29">1.0</entry></row><row><entry>Poem M-200*2</entry><entry align="char" char="." charoff="29">0.3</entry><entry align="char" char="." charoff="29">0.3</entry><entry align="char" char="." charoff="29">0.3</entry></row><row><entry>Purified water</entry><entry align="char" char="." charoff="29">56.1</entry><entry align="char" char="." charoff="29">58.1</entry><entry align="char" char="." charoff="29">63.1</entry></row><row><entry align="right">Total</entry><entry align="char" char="." charoff="29">100.0</entry><entry align="char" char="." charoff="29">100.0</entry><entry align="char" char="." charoff="29">100.0</entry></row></tbody></tgroup><tgroup cols="4" rowsep="0"><colspec colnum="1" colname="col1" colwidth="56mm"/><colspec colnum="2" colname="col2" colwidth="19mm"/><colspec colnum="3" colname="col3" colwidth="19mm"/><colspec colnum="4" colname="col4" colwidth="19mm"/><tbody><row><entry namest="col1" nameend="col4" align="justify">*1 Mydol 12: Kao Co., lauryl glucoside.<br/>
*2 Poem M-200: Riken Vitamin Co., Ltd., glycerol monocaprate.</entry></row></tbody></tgroup></table></tables></p><p id="p0086" num="0086">[Table 5]
<tables id="tabl0005" num="0005"><table frame="all"><title>Table 5 Composition of Hand Lotion (unit: g)</title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="56mm"/><colspec colnum="2" colname="col2" colwidth="30mm"/><thead><row><entry align="center" valign="top"/><entry align="center" valign="top">KSYHL15-1</entry></row></thead><tbody><row><entry>Allantoin</entry><entry align="char" char="." charoff="18">0.1</entry></row><row><entry>Glycyrrhizinate dipotassium</entry><entry align="char" char="." charoff="18">0.1</entry></row><row><entry>Astringent juice of persimmon FD2-2</entry><entry align="char" char="." charoff="18">0.3</entry></row><row><entry>95% ethanol</entry><entry align="char" char="." charoff="18">54.0</entry></row><row><entry>Glycerin</entry><entry align="char" char="." charoff="18">2.0</entry></row><row><entry>Citric acid</entry><entry align="char" char="." charoff="18">0.7</entry></row><row><entry>Trisodium citrate</entry><entry align="char" char="." charoff="18">0.3</entry></row><row><entry>Poem M-200*1</entry><entry align="char" char="." charoff="18">0.3</entry></row><row><entry>Purified water</entry><entry align="char" char="." charoff="18">42.2</entry></row><row><entry align="right">Total</entry><entry align="char" char="." charoff="18">100.0</entry></row></tbody></tgroup><tgroup cols="2" rowsep="0"><colspec colnum="1" colname="col1" colwidth="56mm"/><colspec colnum="2" colname="col2" colwidth="30mm"/><tbody><row><entry namest="col1" nameend="col2" align="justify">*1 Poem M-200: Riken Vitamin Co., Ltd., glycerol monocaprate.</entry></row></tbody></tgroup></table></tables></p><heading id="h0037">[2] Inactivation Test for Norovirus</heading><p id="p0087" num="0087">Ten microliters of each of the hand-washing foaming agents and the hand lotion thus prepared was sufficiently<!-- EPO <DP n="43"> --> mixed with 10 µL of the norovirus test solution and was left stand at room temperature for 30, 60, or 120 seconds. Ten microliters of a total control (phosphate-buffered saline (PBS) alone) was also sufficiently mixed with 10 µL of the norovirus test solution and was left stand at room temperature for 120 seconds. Five microliters of each of these samples was diluted with 2 mL of PBS (400-fold) and was subjected to treatments, such as RNA extraction and cDNA synthesis. Viral genome RNAs remaining in the diluted solution was then counted by real-time PCR.</p><p id="p0088" num="0088">As a control for the samples, 5 µL of each of the hand-washing foaming agents and the hand lotion prepared in Example 2 was diluted with 4 mL of PBS, was sufficiently mixed with 5 µL of the norovirus test solution, and was left stand at room temperature for 120 seconds. After these samples were also subjected to treatments, such as RNA extraction and cDNA synthesis, viral genome RNAs remaining in the solutions were counted by real-time PCR.</p><p id="p0089" num="0089"><figref idrefs="f0001">Fig. 2</figref> shows the results. <figref idrefs="f0001">Fig. 2</figref> shows that the hand-washing foaming agents and the hand lotion prepared in [1] had very high anti-norovirus activity.<!-- EPO <DP n="44"> --></p><heading id="h0038">[EXAMPLE 3]</heading><heading id="h0039">Anti-norovirus Activity Stabilization Test with Vitamin C</heading><p id="p0090" num="0090">[1] The hand-washing foaming agent (KSF15-2) and the hand lotion (KSYHL-5) prepared in Example 2, and the hand-washing foaming agent (KSF15-2) and the hand lotion (KSYHL-5) to which 1% vitamin C was added (KSF15-2(VC) and KSYHL-5(VC), respectively) were subjected to the sunlight for 17 days from February 9 to 26, 2008 (fine weather). A norovirus inactivation test of these four samples and a total control was performed in accordance with the procedures described in Example 2[2] (the contact time between the norovirus test solution and a sample was 2 minutes).</p><p id="p0091" num="0091"><figref idrefs="f0002">Fig. 3</figref> shows the results. <figref idrefs="f0002">Fig. 3</figref> shows that the addition of vitamin C to the hand-washing foaming agents and the hand lotion allowed high anti-norovirus activity to be maintained. The hand-washing foaming agents did not show a significant decrease in activity even in the absence of vitamin C. In contrast, the hand lotion without vitamin C lost anti-norovirus activity in the sunlight.</p><p id="p0092" num="0092">[2] A composition (HA-72) composed of 0.3% persimmon extract (FD2-2 described above), 50% ethanol, 1.6% citric acid, 0.5% trisodium citrate, 0.5% glycerin monocaprate, and water (the<!-- EPO <DP n="45"> --> remainder) was prepared. A composition (HA-72(VC)) composed of 0.3% persimmon extract (FD2-2 described above), 50% ethanol, 1.6% citric acid, 0.5% trisodium citrate, 0.5% glycerin monocaprate, 0.5% vitamin C, and water (the remainder) was prepared. These compositions and KSF15-2(VC) and KSYHL-5(VC) prepared in [1] were subjected to the sunlight for 10 days. A norovirus inactivation test of these four samples was performed in accordance with the procedures described in Example 2[2] (the contact time between the norovirus test solution and a sample was 2 minutes).</p><p id="p0093" num="0093"><figref idrefs="f0002">Fig. 4</figref> shows the results (the mean number of remaining norovirus particles, n = 3). <figref idrefs="f0002">Fig. 4</figref> shows that, like the results of [1], the addition of vitamin C allowed high anti-norovirus activity to be maintained also in an ethanol preparation according to one aspect of the composition.</p><heading id="h0040">[EXAMPLE 4]</heading><heading id="h0041">Synergistic Effect Test of Anti-norovirus Activity Using Citric Acid</heading><p id="p0094" num="0094">An ethanol solution A composed of 0.3% persimmon extract (FD2-2 described above), 50% ethanol, and water (the remainder), an ethanol solution B composed of 0.3% persimmon extract (FD2-2 described above), 1.6% citric acid, 50%<!-- EPO <DP n="46"> --> ethanol, and water (the remainder), and a total control were prepared. A norovirus inactivation test was performed in accordance with the method described in Example 2[2] (the contact time between the norovirus test solution and a sample was 2 minutes).</p><p id="p0095" num="0095"><figref idrefs="f0002">Fig. 4</figref> shows the results. The norovirus survival rate relative to the control (100) was 6.7 for the ethanol solution A and 0.08 for the ethanol solution B, indicating that the addition of citric acid to the persimmon extract and ethanol further increases the anti-norovirus activity.</p></description><claims mxw-id="PCLM56986793" lang="DE" load-source="patent-office"><!-- EPO <DP n="50"> --><claim id="c-de-01-0001" num="0001"><claim-text>Verwendung eines Extrakts aus einer Pflanze der Gattung <i>Diospyros,</i> der Tannin enthält (nachfolgend als "Persimone-Extrakt" bezeichnet), als nichttherapeutischer Desinfektionswirkstoff für ein Norovirus.</claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Verwendung nach Anspruch 1, bei welcher der Persimone-Extrakt hergestellt wird, indem ausgepresster Saft oder ein Extrakt einer Frucht einer Pflanze der Gattung <i>Diospyros</i> erwärmt wird oder der ausgepresste Saft oder der Extrakt mit einem Alkohol behandelt wird.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Verwendung nach Anspruch 1 oder 2, bei welcher der Persimone-Extrakt kondensiertes Tannin enthält.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Verwendung nach einem der Ansprüche 1 bis 3, bei welcher der Persimone-Extrakt aus <i>Diospyros kaki</i> erhalten wird.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Verwendung einer Zusammensetzung, enthaltend:
<claim-text>den Desinfektionswirkstoff gemäß der Definition in einem der Ansprüche 1 bis 4; und</claim-text>
<claim-text>mindestens eine Komponente, die ausgewählt ist aus der Gruppe bestehend aus Alkoholen, Tensiden, antimikrobiellen Wirkstoffen, Befeuchtungsmitteln und kosmetischen Fetten und Ölen</claim-text>
<claim-text>als eine nichttherapeutische Desinfektionszusammensetzung für ein Norovirus.</claim-text><!-- EPO <DP n="51"> --></claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Verwendung nach Anspruch 5, bei welcher die Menge des Persimone-Extrakts (hinsichtlich des Feststoffgehalts) in dem Desinfektionswirkstoff im Bereich von 0,01 Gew.-% bis 5 Gew.-% der Gesamtmenge der Zusammensetzung liegt.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Verwendung nach Anspruch 5 oder 6, bei welcher die Zusammensetzung ferner eine organische Säure und/oder ein Salz derselben enthält.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Verwendung nach Anspruch 7, bei welcher die organische Säure Zitronensäure und/oder ein Salz derselben ist.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Verwendung nach einem der Ansprüche 5 bis 8, bei welcher die Zusammensetzung ferner Vitamin C enthält.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Verwendung nach einem der Ansprüche 5 bis 9, bei welcher die Zusammensetzung ein Alkoholpräparat ist, das den Desinfektionswirkstoff und einen Alkohol enthält.</claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Verwendung nach einem der Ansprüche 5 bis 9, bei welcher die Zusammensetzung eine Waschzusammensetzung ist, die den Desinfektionswirkstoff und ein Tensid enthält.</claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Verwendung nach einem der Ansprüche 5 bis 9, bei welcher die Zusammensetzung ein Desinfektionsmittel ist, das den Desinfektionswirkstoff und einen antimikrobiellen Wirkstoff enthält.</claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Verwendung nach einem der Ansprüche 5 bis 9, bei welcher die Zusammensetzung eine Lotion, eine milchige Lotion oder eine Creme ist, die den Desinfektionswirkstoff und mindestens eine Komponente, die ausgewählt ist aus der Gruppe bestehend aus einem Befeuchtungsmittel und einem kosmetischen Fett und Öl, enthält.<!-- EPO <DP n="52"> --></claim-text></claim><claim id="c-de-01-0014" num="0014"><claim-text>Pharmazeutische Zusammensetzung, enthaltend einen Extrakt aus einer Pflanze der Gattung Diospyros, der Tannin enthält, zur Verwendung bei der Behandlung einer durch Norovirus verursachten Infektionserkrankung.</claim-text></claim></claims><claims mxw-id="PCLM56986794" lang="EN" load-source="patent-office"><!-- EPO <DP n="47"> --><claim id="c-en-01-0001" num="0001"><claim-text>The use of an extract from a plant of the genus <i>Diospyros</i> containing tannin (hereinafter referred to as a "persimmon extract") as a non-therapeutic disinfecting agent for a norovirus.</claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>The use according to Claim 1, wherein the persimmon extract is produced by heating squeezed juice or an extract of a fruit of a plant of the genus <i>Diospyros</i> or treating the squeezed juice or the extract with an alcohol.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The use according to Claim 1 or 2, wherein the persimmon extract comprises condensed tannin.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>The use according to any one of Claims 1 to 3, wherein the persimmon extract is obtained from <i>Diospyros kaki.</i></claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>The use of a composition comprising:
<claim-text>the disinfecting agent as defined in any one of Claims 1 to 4; and</claim-text>
<claim-text>at least one component selected from the group consisting of alcohols, surfactants, antimicrobial agents, humectants, and cosmetic fats and oils<!-- EPO <DP n="48"> --></claim-text>
<claim-text>as a non-therapeutic disinfecting composition for a norovirus.</claim-text></claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>The use according to Claim 5, wherein the amount of the persimmon extract (in terms of solid content) in the disinfecting agent ranges from 0.01% to 5% by weight of the total amount of the composition.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>The use according to Claim 5 or 6, wherein the composition further comprises an organic acid and/or a salt thereof.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>The use according to Claim 7, wherein the organic acid and/or a salt thereof is citric acid and/or a salt thereof.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>The use according to any one of Claims 5 to 8, wherein the composition further comprises vitamin C.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>The use according to any one of Claims 5 to 9, wherein the composition is an alcohol preparation comprising the disinfecting agent and an alcohol.<!-- EPO <DP n="49"> --></claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>The use according to any one of Claims 5 to 9, wherein the composition is a washing composition comprising the disinfecting agent and a surfactant.</claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>The use according to any one of Claims 5 to 9, wherein the composition is a disinfectant comprising the disinfecting agent and an antimicrobial agent.</claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>The use according to any one of Claims 5 to 9, wherein the composition is a lotion, a milky lotion, or a cream comprising the disinfecting agent and at least one component selected from the group consisting of a humectant and a cosmetic fat and oil.</claim-text></claim><claim id="c-en-01-0014" num="0014"><claim-text>A pharmaceutical composition comprising an extract from a plant of the genus Diospyros containing tannin for use in the treatment of an infectious disease caused by norovirus.</claim-text></claim></claims><claims mxw-id="PCLM56986795" lang="FR" load-source="patent-office"><!-- EPO <DP n="53"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Utilisation d'un extrait d'une plante du genre <i>Diospyros</i> contenant du tanin (dans la suite du document mentionné en tant que « extrait de kaki ») comme agent de désinfection non thérapeutique pour un norovirus.</claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Utilisation selon la revendication 1, dans laquelle l'extrait de kaki est produit en chauffant du jus pressé ou un extrait d'un fruit d'une plante du genre <i>Diospyros</i> ou en traitant le jus pressé ou l'extrait avec un alcool.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Utilisation selon la revendication 1 ou 2, dans laquelle l'extrait de kaki comprend du tanin condensé.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Utilisation selon l'une quelconque des revendications 1 à 3, dans laquelle l'extrait de kaki est obtenu à partir de <i>Diospyros kaki.</i></claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Utilisation d'une composition comprenant :
<claim-text>l'agent de désinfection tel que défini selon l'une quelconque des revendications 1 à 4 ; et</claim-text>
<claim-text>au moins un composant sélectionné à partir du groupe constitué par des alcools, des agents de surface, des agents antimicrobiens, des humidifiants et des graisses et huiles cosmétiques en tant que composition de désinfection non thérapeutique pour un norovirus.</claim-text></claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Utilisation selon la revendication 5, dans laquelle la quantité de l'extrait de kaki (en termes de teneur en solide) dans l'agent de désinfection s'étend de 0,01 % à 5 % en poids de la quantité totale de la composition.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Utilisation selon la revendication 5 ou 6, dans laquelle la composition comprend en outre un acide organique et/ou un sel de celui-ci.<!-- EPO <DP n="54"> --></claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Utilisation selon la revendication 7, dans laquelle l'acide organique et/ou un sel de celui-ci est l'acide citrique et/ou un sel de celui-ci.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Utilisation selon l'une quelconque des revendications 5 à 8, dans laquelle la composition comprend en outre de la vitamine C.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Utilisation selon l'une quelconque des revendications 5 à 9, dans laquelle la composition est une préparation d'alcool comprenant l'agent de désinfection et un alcool.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>Utilisation selon l'une quelconque des revendications 5 à 9, dans laquelle la composition est une composition de lavage comprenant l'agent de désinfection et un agent de surface.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>Utilisation selon l'une quelconque des revendications 5 à 9, dans laquelle la composition est un désinfectant comprenant l'agent de désinfection et un agent antimicrobien.</claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>Utilisation selon l'une quelconque des revendications 5 à 9, dans laquelle la composition est une lotion, une lotion laiteuse, ou une crème comprenant l'agent de désinfection et au moins un composant sélectionné à partir du groupe constitué par un humidifiant et une graisse et une huile cosmétiques.</claim-text></claim><claim id="c-fr-01-0014" num="0014"><claim-text>Composition pharmaceutique comprenant un extrait d'une plante du genre <i>Diospyros</i> contenant du tanin à utiliser dans le traitement d'une maladie infectieuse provoquée par un norovirus.</claim-text></claim></claims><drawings mxw-id="PDW16672555" load-source="patent-office"><!-- EPO <DP n="55"> --><figure id="f0001" num="1(a),1(b),1(c),2"><img id="if0001" file="imgf0001.tif" wi="165" he="193" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="56"> --><figure id="f0002" num="3,4"><img id="if0002" file="imgf0002.tif" wi="165" he="201" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="57"> --><figure id="f0003" num="5"><img id="if0003" file="imgf0003.tif" wi="165" he="103" img-content="drawing" img-format="tif"/></figure></drawings><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
